Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis
Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.
EP: 1.Heterogenous Presentation of Atopic Dermatitis
EP: 2.Burden of Atopic Dermatitis and its Impact on Patient’s Quality of Life
EP: 3.Patient’s Goals and Atopic Dermatitis Treatment Selection
EP: 4.Talking to Patients about Atopic Dermatitis Treatment Response
EP: 5.Use of PRO in Atopic Dermatitis Clinical Practice
EP: 6.Incorporating Patient Preferences in the Treatment of Atopic Dermatitis
EP: 7.Changing Standard of Care in Atopic Dermatitis
EP: 8.Unmet Needs and Gaps in AD
EP: 9.Looking Beyond Type 2 Inflammation in Atopic Dermatitis
EP: 10.JAK Inhibitors in Atopic Dermatitis
EP: 11.Safety Profile of JAK Inhibitors and their Use in Atopic Dermatitis
Now Viewing
EP: 12.Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis
Video content above is prompted by the following:
- What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment?
Recent Videos
Related Content
